These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1868 related articles for article (PubMed ID: 33725836)

  • 1. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
    Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
    Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
    Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
    Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review.
    Xu QY; Yang HY; Li MW; He ZD; Hong HY; Peng ZG
    Medicine (Baltimore); 2022 Sep; 101(38):e30731. PubMed ID: 36197207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.
    Tian XP; Cai J; Xia Y; Zhang YC; Wang L; Liu PP; Huang HQ; Li YJ; Zhou H; Li ZM; Yang J; Wei LQ; Zou QH; Huang Y; Li J; Ling L; Zhong WL; Cai QQ
    Lancet Haematol; 2024 May; 11(5):e336-e344. PubMed ID: 38554717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
    Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
    Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review.
    Li L; Wu C; Chai Y; Dong C; Zhao L
    Int J Immunopathol Pharmacol; 2021; 35():20587384211009342. PubMed ID: 33845613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
    Wei W; Wu P; Li L; Zhang ZH
    Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Sandwich" protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study.
    Shen CQ; He GQ; Wan Z; Lin C; Yang X; Lu XX; Zhu YP; Gao J; Guo X
    Ann Hematol; 2023 Nov; 102(11):3143-3152. PubMed ID: 37486391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
    Wang H; Wuxiao ZJ; Zhu J; Wang Z; Wang KF; Li S; Chen X; Lu Y; Xia ZJ
    Leuk Lymphoma; 2015 Apr; 56(4):971-7. PubMed ID: 24991715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
    Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
    Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
    Wei YC; Qi F; Zheng BM; Zhang CG; Xie Y; Chen B; Liu WX; Liu WP; Fang H; Qi SN; Zhang D; Chai Y; Li YX; Wang WH; Song YQ; Zhu J; Dong M
    Int J Cancer; 2023 Nov; 153(9):1643-1657. PubMed ID: 37539660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.
    Du L; Zhang L; Li L; Li X; Yan J; Wang X; Fu X; Sun Z; Zhang X; Li Z; Wu J; Yu H; Chang Y; Zhou Z; Nan F; Wu X; Tian L; Zhang M
    Onco Targets Ther; 2020; 13():7189-7197. PubMed ID: 32801749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
    Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
    Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report.
    Wang J; Gao YS; Xu K; Li XD
    World J Clin Cases; 2022 Feb; 10(5):1609-1616. PubMed ID: 35211600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
    Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
    Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
    Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
    Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
    Wu W; Chen X; Li N; Luo Q; Zou L
    Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.